Literature DB >> 8005802

Comparison of the effects of hydralazine on tumor and normal tissue blood perfusion by MRI.

C A Belfi1, C R Paul, S Shan, F Q Ngo.   

Abstract

PURPOSE: The differential effects on blood perfusion of the vasodilator hydralazine (HYD) between tumor and normal muscle have been measured using the dynamic enhanced-magnetic resonance imaging (DE-MRI) technique. METHODS AND MATERIALS: DE-MRI is a noninvasive method of determining blood perfusion in tumors and normal tissues using the MR contrast agent Gd-DTPA. Hydralazine is currently being used in an attempt to increase tumor response to bioreductive agents and to hyperthermia.
RESULTS: We show that a dose of 1.2 mg/kg HYD causes an increase in tumor perfusion while doses > or = 2.5 mg/kg cause a decrease in tumor perfusion. The latter was accompanied by a dose-dependent increase in normal muscle perfusion consistent with the "steal effect."
CONCLUSION: This study demonstrates the sensitivity of the DE-MRI technique and its capability of providing estimates of blood perfusion in normal and tumor tissue as well as in smaller regions of a solid tumor. Such features would make it clinically useful in the study of tumor response to radiation therapy and chemotherapy in patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005802     DOI: 10.1016/0360-3016(94)90441-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Authors:  Michael Kragh; Bjørn Quistorff; Michael R Horsman; Paul E G Kristjansen
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

2.  Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy.

Authors:  Benjamin L Viglianti; Michael Lora-Michiels; Jeanie M Poulson; Lan Lan; Daohai Yu; Dahio Yu; Linda Sanders; Oana Craciunescu; Zeljko Vujaskovic; Donald E Thrall; James Macfall; Cecil H Charles; Terence Wong; Mark W Dewhirst
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

3.  DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study.

Authors:  Oana I Craciunescu; Kimberly L Blackwell; Ellen L Jones; James R Macfall; Daohai Yu; Zeljko Vujaskovic; Terence Z Wong; Vlayka Liotcheva; Eric L Rosen; Leonard R Prosnitz; Thaddeus V Samulski; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2009       Impact factor: 3.914

Review 4.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

5.  Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.

Authors:  Eugene Manley; David J Waxman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

6.  Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life.

Authors:  Hemant Sarin; Ariel S Kanevsky; Steve H Fung; John A Butman; Robert W Cox; Daniel Glen; Richard Reynolds; Sungyoung Auh
Journal:  J Transl Med       Date:  2009-05-13       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.